Gibson Christopher sells Recursion Pharmaceuticals (RXRX) stock for $130k

Director Christopher Gibson sold 40,000 Recursion (NASDAQ: RXRX) Class A shares at $3.25 on Mar 23, 2026 for $130,000 and converted 40,000 Class B into Class A at $0; post-transactions he directly owns 906,556 Class A and indirectly holds 824,000 Class B via affiliated entities. Recursion reported Q4 2025 EPS of -$0.21 (vs -$0.30 forecast) and revenue of $35.54M (+45% vs expectations); the stock trades near a 52-week low of $2.98 and is down ~51% over the past year. BofA cut its price target from $7.00 to $6.00 (Neutral), citing the need for repeatable clinical successes and noting most clinical value is expected in 2027; Vicki Goodman will become CMO effective Apr 6, 2026.

Analysis

Market pricing today appears to bake in both high execution risk for AI-derived biology and a multi-year timeline to commercial value, leaving asymmetric upside if Recursion can string together repeatable, non-marginal clinical signals. A single robust proof-of-concept in a clearly defined oncology subpopulation could compress uncertainty and trigger a valuation re-rating of 1.5x–3x within 6–18 months as investors re-price probability-of-success across the pipeline rather than a binary platform bet.

The new medical leadership and recent governance actions are second-order de-riskers: better protocol design and fewer amendments can shave 3–9 months off key readout timelines and materially reduce near-term cash burn from prolonged dose-escalation cohorts. Conversely, any increase in free float/liquidity from share-class changes can amplify downside on minor misses — larger trading volumes will accelerate mark-to-market moves on headline news.

Key risks are classic platform biotech: single-trial failures, faster-than-expected cash depletion, and narrative fatigue among quant/AI investors. Monitor three horizons: weeks–months for enrollment and interim data items, 6–18 months for pivotal or multi-cohort readouts that change PoS, and 18–36 months for commercial proof and partnership/BD transactions that realize upside. The trade is time- as much as outcome-dependent; calibration of exposure should match milestone cadence rather than static conviction.

Key Decisions for Investors

• Initiate a staged long position in RXRX equal to 1–1.5% of portfolio capital, adding into positive early biomarkers; immediately buy 6–9 month puts ~25–30% OTM as downside protection. R/R: asymmetric upside to 100–200% on positive sequencing vs limited downside capped by puts (cost ≈ 3–8% of notional).
• Buy an 18–24 month call spread on RXRX (long nearer-term OTM call / short higher-strike call) to capture multi-quarter de-risking into clinical readouts while capping premium; target 2:1 payoff-to-cost with break-even at ~60–80% upside. Use as a high-conviction, limited-loss levered exposure.
• Pair trade: long RXRX equity (0.75% portfolio) / short XBI (0.75%) to isolate company-specific platform upside and hedge sector-wide volatility. This reduces macro biotech beta while keeping directional exposure to Recursion’s execution.
• Watch CRO/outsourcer exposure (e.g., IQV) as a conditional long: if interim data signals are positive and timelines accelerate, initiate 6–12 month long positions in IQV/IQVIA to capture incremental outsourcing demand; small tactical position (0.5–1%) with stop-loss on reversal of RXRX readouts.